دورية أكاديمية
Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.
| العنوان: | Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials. |
|---|---|
| المؤلفون: | Jacobsen, Laura M, Cuthbertson, David, Bundy, Brian N, Atkinson, Mark A, Moore, Wayne, Haller, Michael J, Russell, William E, Gitelman, Stephen E, Herold, Kevan C, Redondo, Maria J, Sims, Emily K, Wherrett, Diane K, Moran, Antoinette, Pugliese, Alberto, Gottlieb, Peter A, Sosenko, Jay M, Ismail, Heba M |
| المصدر: | Diabetes Care ; ISSN:1935-5548 ; Volume:47 ; Issue:6 |
| بيانات النشر: | Silverchair Information Systems |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| الوصف: | Mixed-meal tolerance test-stimulated area under the curve (AUC) C-peptide at 12-24 months represents the primary end point for nearly all intervention trials seeking to preserve β-cell function in recent-onset type 1 diabetes. We hypothesized that participant benefit might be detected earlier and predict outcomes at 12 months posttherapy. Such findings would support shorter trials to establish initial efficacy. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.2337/dc24-0171Test; https://pubmed.ncbi.nlm.nih.gov/38621411Test |
| DOI: | 10.2337/dc24-0171 |
| الإتاحة: | https://doi.org/10.2337/dc24-0171Test https://pubmed.ncbi.nlm.nih.gov/38621411Test |
| حقوق: | © 2024 by the American Diabetes Association. |
| رقم الانضمام: | edsbas.81415A93 |
| قاعدة البيانات: | BASE |
| DOI: | 10.2337/dc24-0171 |
|---|